CryoLife
Market Cap
US$884.5m
Last Updated
2021/04/12 22:06 UTC
Data Sources
Company Financials +
Executive Summary
CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential and overvalued.
Similar Companies
Share Price & News
How has CryoLife's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRY is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CRY's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
0.3%
CRY
1.6%
US Medical Equipment
0.9%
US Market
1 Year Return
14.0%
CRY
42.5%
US Medical Equipment
57.9%
US Market
Return vs Industry: CRY underperformed the US Medical Equipment industry which returned 40.4% over the past year.
Return vs Market: CRY underperformed the US Market which returned 56.3% over the past year.
Shareholder returns
| CRY | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.3% | 1.6% | 0.9% |
| 30 Day | -10.3% | 4.1% | 2.3% |
| 90 Day | -10.0% | 2.5% | 6.3% |
| 1 Year | 14.0%14.0% | 43.7%42.5% | 60.8%57.9% |
| 3 Year | 1.0%1.0% | 75.8%71.7% | 64.5%53.9% |
| 5 Year | 78.8%78.8% | 140.8%124.1% | 120.9%96.4% |
Long-Term Price Volatility Vs. Market
How volatile is CryoLife's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
CryoLife (NYSE:CRY) Seems To Be Using A Lot Of Debt8 months ago | Simply Wall St
The CryoLife (NYSE:CRY) Share Price Is Up 77% And Shareholders Are Holding On1 year ago | Simply Wall St
Is CryoLife, Inc.'s (NYSE:CRY) CEO Pay Justified?Valuation
Is CryoLife undervalued compared to its fair value and its price relative to the market?
2.66x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CRY's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CRY's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CRY is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: CRY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CRY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CRY is good value based on its PB Ratio (2.7x) compared to the US Medical Equipment industry average (5x).
Future Growth
How is CryoLife forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
75.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CRY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CRY's is expected to become profitable in the next 3 years.
Revenue vs Market: CRY's revenue (11.9% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: CRY's revenue (11.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CRY's Return on Equity is forecast to be high in 3 years time
Past Performance
How has CryoLife performed over the past 5 years?
-62.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRY is currently unprofitable.
Growing Profit Margin: CRY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CRY is unprofitable, and losses have increased over the past 5 years at a rate of 62.6% per year.
Accelerating Growth: Unable to compare CRY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).
Return on Equity
High ROE: CRY has a negative Return on Equity (-5.07%), as it is currently unprofitable.
Financial Health
How is CryoLife's financial position?
Financial Position Analysis
Short Term Liabilities: CRY's short term assets ($234.6M) exceed its short term liabilities ($60.5M).
Long Term Liabilities: CRY's short term assets ($234.6M) do not cover its long term liabilities ($400.2M).
Debt to Equity History and Analysis
Debt Level: CRY's debt to equity ratio (88.7%) is considered high.
Reducing Debt: CRY's debt to equity ratio has increased from 1% to 88.7% over the past 5 years.
Debt Coverage: CRY's debt is not well covered by operating cash flow (4.2%).
Interest Coverage: CRY is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Dividend
What is CryoLife current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CRY is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.3yrs
Average management tenure
CEO
Pat Mackin (53 yo)
6.58yrs
Tenure
US$3,415,458
Compensation
Mr. James Patrick Mackin, also known as Pat, has been the Chief Executive Officer and President of CryoLife Inc. since September 02, 2014 and has been its Chairman since May 2015. Mr. Mackin served as Pres...
CEO Compensation Analysis
Compensation vs Market: Pat's total compensation ($USD3.42M) is above average for companies of similar size in the US market ($USD2.16M).
Compensation vs Earnings: Pat's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: CRY's management team is seasoned and experienced (6.3 years average tenure).
Board Members
Experienced Board: CRY's board of directors are considered experienced (8.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CRY insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.8%.
Top Shareholders
Company Information
CryoLife, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: CryoLife, Inc.
- Ticker: CRY
- Exchange: NYSE
- Founded: 1984
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$884.501m
- Shares outstanding: 39.12m
- Website: https://www.cryolife.com
Number of Employees
Location
- CryoLife, Inc.
- 1655 Roberts Boulevard N.W.
- Kennesaw
- Georgia
- 30144
- United States
Listings
Biography
CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linki...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/12 22:06 |
| End of Day Share Price | 2021/04/12 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.